medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 6

<< Back Next >>

Gac Med Mex 2015; 151 (6)

Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)

Delgado-García G, Monreal-Robles R, Gallegos-Arguijo D, Marfil-Rivera J

Language: Spanish
References: 14
Page: 798-801
PDF size: 66.08 Kb.


ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition caused by antibodies against the heparin-PF4 complex. This disorder is even more problematic in patients undergoing hemodialysis since they are repeatedly exposed to heparin. The diagnostic and therapeutic approach is particularly challenging in this population. We report the case of a woman with chronic kidney disease and a high pretest probability for heparin-induced thrombocytopenia who was acutely treated with apixaban, an oral selective factor Xa inhibitor.


REFERENCES

  1. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost. 2014;40(1): 106-14.

  2. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-18.

  3. Go´zdzikiewicz J, Borawski J, My´sliwiec M. Treatment of heparin-induced thrombocytopenia type II in hemodialysis patients: the search for a Holy Grail continues. Clin Appl Thromb Hemost. 2007;13(1):110-1.

  4. Syed S, Reilly RF. Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol. 2009;5(9):501-11.

  5. Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant. 2007;22(6):1680-4.

  6. Lee GM, Arepally GM. Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):541-63.

  7. Eliquis[package insert]. Princeton, New Jersey: Bristol-Meyers Squibb; 2012 [Revised: 01/2014].

  8. Walenga JM, Prechel M, Hoppensteadt D, et al. Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2013;19(5):482-7.

  9. Gafter U, Bessler H, Malachi T, et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron. 1987;45(3): 207-10.

  10. Dorgalaleh A, Mahmudi M, Tabibian S, et al. Anemia and thrombocytopenia in acute and chronic renal failure. Int J Hematol Oncol Stem Cell Res. 2013;7(4):34-9.

  11. Ho SJ, Gemmell R, Brighton TA. Platelet function testing in uraemic patients. Hematology. 2008;13(1):49-58.

  12. Kim HY, Oak CY, Kim MJ, et al. Prevalence and associations for abnormal bleeding times in patients with renal insufficiency. Platelets. 2013;24(3):213-8.

  13. Canaud B, Polito-Bouloux C, Garred LJ, et al. Recombinant human erythropoietin: 18 months’ experience in hemodialysis patients. Am J Kidney Dis. 1990;15(2):169-75.

  14. Thachil J, Szeki I. Erythropoietin corrects thrombocytopenia. Am J Med. 2013;126(10):e3-4.




2020     |     www.medigraphic.com